High dose interleukin-2 (Aldesleukin) - expert consensus on best management practices-2014

Interleukin-2 (IL-2) was historically one of the few treatments for adults with stage IV solid tumors that could produce complete responses (CRs) that were often durable for decades without further therapy. The majority of complete responders with metastatic renal cell carcinoma (mRCC) and metastati...

Descripción completa

Detalles Bibliográficos
Autores principales: Dutcher, Janice P, Schwartzentruber, Douglas J, Kaufman, Howard L, Agarwala, Sanjiv S, Tarhini, Ahmad A, Lowder, James N, Atkins, Michael B
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2014
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6889624/
https://www.ncbi.nlm.nih.gov/pubmed/31546315
http://dx.doi.org/10.1186/s40425-014-0026-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6889624/
https://www.ncbi.nlm.nih.gov/pubmed/31546315
http://dx.doi.org/10.1186/s40425-014-0026-0

Ejemplares similares